contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


valberedning-for-biovica-international-ab-infor-arsstamman-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB 11.9 julkaistu osavuosi Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mitä tapahtuu.     SEK 000s Q1 25/26 Q1 24/25 May-April 24/25     Net sales 2,596 1,714 8,619   Operating profit (loss) -19,334 -23,562 -85,839   Earnings per share, after dilution -0.18 -0.27 -0.95   Number of shares at the end of the period 97,786,384 84,055,560 92,569,248   Cash and cash equivalents at the end of the period 16,305 65,209 24,415   Cash flow from operating activities -17,196 -29,044 -85,367   Average number of employees 25 27 26    Significant events during the first quarter   Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa   Biovica signed a significant Master Service Agreement (MSA) and first work order under that agreement for SEK 4 million   New data on DiviTum TKa for use in three areas of cancer presented at ASCO   Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business   Biovica announced financial targets reflecting its important partnership and commercial success   Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share   Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA   Significant events after the end of the period   Biovica has been granted a new European patent   Biovica received the fourth work order from one of its Tier 1 pharma companies, this time for SEK 3 million.   Biovica launched DiviTum TKa for use in early breast cancer   Biovica carried out a directed share issue for approximately SEK 42.2 million

Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval in 2022. The small company has faced challenges in launching the product in the US market, and the start of sales has taken longer than expected. They are now aiming to commercialize the DiviTum TKa test with Tempus AI. In the last fiscal year, revenue was approximately 8 million SEK. The goal is to increase sales to 50 million Swedish kronor in fiscal year 2025/2026, mainly from US sales. More information on targets: Biovica announces financial targets following key partnerships and commercial progress - Biovica International AB They just raised 122 million SEK from a share issue for growth. The company’s market capitalization is 195 million SEK. Redeye report from June before the share issue https://www.redeye.se/api/articles/download-file/3584aa8d-b126-374e-90eb-e24a8a216c76/Biovica%3A%20Adding%20cash%20and%20increased%20market%20distribution

Biovica International

Valberedningen inför årsstämman 2026 ska bestå av fyra ledamöter, vilka skall representera de tre aktieägare med högst antal aktier som accepterar uppdraget att ingå i valberedningen per den...

<div class="mfn-preamble"><p><strong>Valberedningen inför årsstämman 2026 ska bestå av fyra ledamöter, vilka skall representera de tre aktieägare med högst antal aktier som accepterar uppdraget att ingå i valberedningen per den 31 december 2025, samt styrelsens ordförande. Valberedningen utser sedan inom sig ordförande.</strong></p></div><div class="mfn-body"><p>I enlighet med ovanstående riktlinjer kommer valberedningen inför årsstämman 2026 att utgöras av följande personer:</p><ul><li>Anna Rylander Eklund representerande familjen Rylander med bolag.</li><li>Carlo Bogerd, representerande Bogerd Family Office med bolag.</li><li>Peter Høngaard Andersen, representerande aktieägaren Fredrik Lundgren</li><li>Fredrik Alpsten, styrelsens ordförande</li></ul><p>Ledamöterna i valberedningen representerar tillsammans cirka&nbsp;39 procent av aktierna och 44 procent av rösterna i bolaget sett till den&nbsp;31 december 2025.</p><p>Valberedningens övergripande ansvar är att lämna förslag avseende ordförande vid årsstämma, val och arvodering av styrelseledamöter, val och arvodering av revisor samt principer för utseende av valberedning och instruktioner för valberedning.</p><p>Aktieägare som önskar lämna förslag till bolagets valberedning kan göra det via e-post till <a href="mailto:ir@biovica.com" rel="noopener">ir@biovica.com</a> eller med brev till adressen: Biovica International AB, Att: Valberedningen, Dag Hammarskjölds väg 54B, 752 37 Uppsala.</p></div><div class="mfn-footer mfn-26074c3d2267"><p><strong class="mfn-heading-1">Kontakt</strong></p><hr><p>Fredrik Alpsten, Ordförande<br>+46 70 667 31 06<br><a href="mailto:fredrik@alpstenconsulting.com" rel="noopener">fredrik@alpstenconsulting.com</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br><br>Anders Rylander, VD<br>Telefon: +46 76 666 16 47<br>E-post:&nbsp;<a href="mailto:anders.rylander@biovica.com" rel="noopener">anders.rylander@biovica.com</a></p></div><div class="mfn-footer mfn-about mfn-3dbc25e51d95"><p><strong class="mfn-heading-1">Biovica – Behandlingsbeslut med större säkerhet</strong></p><hr><p>Biovica utvecklar och kommersialiserar blodbaserade biomarköranalyser som hjälper onkologer att övervaka cancerprogression. Biovicas analys, DiviTum® TKa, mäter cellproliferation genom att detektera TKa-biomarkören i blodomloppet. Den första applikationen för DiviTum® TKa-testet är behandlingsövervakning av patienter med spridd bröstcancer. Biovicas vision är: "Förbättrad vård för cancerpatienter." Biovica samarbetar med världsledande cancerinstitut och läkemedelsföretag. DiviTum® TKa har fått FDA 510(k)-godkännande i USA och är CE-märkt i EU. Biovicas aktier handlas på Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB är företagets Certified Adviser. För mer information, besök: www.biovica.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/7fcf1327-d6f5-4b78-85e2-055c92a1aedd/valberedning-for-biovica-international-ab-infor-arsstamman-2026.pdf" rel="noopener">Valberedning för Biovica International AB inför årsstämman 2026</a></p></div>

Valberedning för Biovica International AB inför årsstämman 2026

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

Vad betyder ATH?

Dollarns dominans – ohotad eller sårbar?  Om dollarns position som världsvaluta 